Navigation Links
Diabetes drug could treat leading cause of blindness
Date:5/7/2012

University of Texas Medical Branch at Galveston researchers have discovered that a drug already prescribed to millions of people with diabetes could also have another important use: treating one of the world's leading causes of blindness.

In laboratory rat and cell-culture experiments, the scientists found that metformin, which is commonly used to control blood sugar levels in type 2 diabetes, also substantially reduced the effects of uveitis, an inflammation of the tissues just below the outer surface of the eyeball. Uveitis causes 10 to 15 percent of all cases of blindness in the United States, and is responsible for an even higher proportion of blindness globally. The only treatment now available for the disorder is steroid therapy, which has serious side effects and cannot be used long-term.

"Uveitis has various causes the most common are infectious diseases and autoimmune disorders but they all produce inflammation within the eye," said UTMB professor Kota V. Ramana, senior author of a paper on the study now online in the journal Investigative Ophthalmology & Visual Science. "Metformin inhibits the process that causes that inflammation."

The scientists discovered metformin's efficacy when they tested it in rats given an endotoxin that mimicked the inflammatory effects of bacterial infection. The results showed clearly that metformin was a very effective anti-uveitis agent.

"We found that the drug is therapeutic as well as preventive if we gave our rats the drug beforehand, they didn't develop uveitis, and if we gave it after uveitis had developed, it was therapeutic," said UTMB professor Satish Srivastava, also an author of the IOVS paper. "Metformin's strong anti-inflammatory properties make this possible."

According to the researchers, metformin works by activating an enzyme called AMPK, which in turn damps down the activity of the protein NF-kappa B. The inhibition of NF-kappa B suppresses the prod
'/>"/>

Contact: Jim Kelly
jpkelly@utmb.edu
409-772-8791
University of Texas Medical Branch at Galveston
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Study identifies possible protective blood factors against Type 2 diabetes
2. New research finds no association between white potato consumption (baked, boiled mashed) and obesity, Type 2 diabetes or systemic inflammation
3. Xenotransplantation as a therapy for type 1 diabetes
4. Value of Metformin, Insulin Combo for Type 2 Diabetes Questioned
5. Diabetes Groups Issue New Guidelines on Blood Sugar
6. Cellular pathway linked to diabetes, heart disease
7. Naturopathic care can improve blood sugar, mood in diabetes
8. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
9. Common Plastics Chemical Might Boost Diabetes Risk
10. Mouse Study Hints at New Path for Diabetes Treatment
11. Disrupted Sleep May Raise Risk for Obesity, Diabetes: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... could help doctors predict which patients might suffer potentially ... The program, which assesses brain scans using pattern recognition ... passport control, has been developed by researchers at Imperial ... the Wellcome Trust, which used the software are published ... Stroke affects over 15 million people each year worldwide. ...
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... the journal Oncotarget , explored tumour heterogeneity ... their own DNA signatures within the same cancer. ... effective, targeted treatment strategies. , Firstly they confirmed ... either the KRAS or BRAF mutation. Secondly, they ... gene mutation have that specific mutation present uniformly ...
(Date:4/22/2014)... and industry leaders visited the New Jersey Institute ... Joel S. Bloom for the launch of the ... that provides a new model for business innovation ... education assets and investment. U.S. Senator Cory Booker, ... Joe Taylor, New Jersey Lieutenant Governor Kim Guadagno, ...
(Date:4/22/2014)... cancers are small cell lung cancers (SCLC), which ... However, researchers at Virginia Commonwealth University Massey Cancer ... leading to this resistance that may lead to ... mediating B-cell lymphoma 2 (Bcl-2) family proteins, which ... their function, this family of proteins can trigger ...
Breaking Medicine News(10 mins):Health News:Airport security-style technology could help doctors decide on stroke treatment 2Health News:Airport security-style technology could help doctors decide on stroke treatment 3Health News:More Americans in their golden years are going hungry 2Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2
... MINNEAPOLIS, July 27 ATS Medical, Inc. (Nasdaq: ATSI ... today announced that it will release financial results for the second ... August 3, 2009. The Company will host a conference call ... Time (2:00 p.m. Pacific Time) to discuss its second quarter results ...
... ... ... 2009 -- Silver Creek Systems®, the pioneer and leader in automated Data Mastering, announced ... Management from Forrester Research, Inc., author Rob Karel recognizes the value the company delivers ...
... Midbrook is using ... use in hospitals and other medical facilities that are working to prevent infections. , ... (Vocus) July 27, 2009 -- Midbrook, ... case carts and storage cabinets has begun to use copper alloys as an alternative ...
... ... a large pill. Impact Nutritionals, Inc. launches its first product, S7 Prenatal™ Drink Mix, the ... premise that supplements should taste good and be good for you. To celebrate the launch, ... , ...
... ... in a state of crisis largely due to the failure of highly ... individuals. In his latest article, The Perfect Health Plan: Proven, Safe, Effective, ... occur per year from these FDA approved, properly prescribed, and properly administered ...
... Government health officials from 13 African countries today ... medical laboratories, starting a process that the World Health ... an historic step to strengthen health systems and lead ... of Africa,s laboratories are now accredited, in part because ...
Cached Medicine News:Health News:ATS Medical Announces Second Quarter 2009 Earnings Release Date and Conference Call 2Health News:Leading Independent Analyst Firm States Silver Creek Systems Holds A Virtual Monopoly In Delivering Advanced Product Data Quality Capabilities 2Health News:Midbrook Utilizes Copper in Medical Environments 2Health News:Moms, Registered Dietitian, Develop the First All-In-One Prenatal Vitamin in a Great Tasting Drink Mix 2Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 2Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 3Health News:Research Scientist Reports On Time-Tested Solution To Current Medical Crisis 4Health News:Leading health organizations launch new accreditation process for laboratories across Africa 2Health News:Leading health organizations launch new accreditation process for laboratories across Africa 3Health News:Leading health organizations launch new accreditation process for laboratories across Africa 4
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will ... Journal of Drugs in Dermatology (JDD) at ... The event is January 17-20, 2014, at the Omni Orlando Resort ... The ODAC is a distinguished event that ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... positive,results from a Phase I trial of R1507, a ... in patients with solid,tumors. IGF-1 is one of the ... pathways, which promote cell growth and cell survival. The,IGF-1R ... role in mediating,the resistance to cytotoxic drugs and EGFR/HER2-targeted ...
... tolerated dose for trodusquemine determined, PLYMOUTH MEETING, ... ) today presented data from its dose-escalating,Phase 1 ... candidate for the treatment of obesity. In the ... clinical doses, and,no serious adverse events were seen ...
Cached Medicine Technology:Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 2Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 3Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507) 4Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 2Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 3Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 4Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting 5
... IV and the Penilab V have an exceptionally sensitive ... is similar to the Model 1061 shown below, but ... added later. The Penilab V has a Doppler. ... accessories you'll need to get started. Latex rubber ...
... is designed for vascular labs already ... Its primary use will be ... a cuff with air. Blood ... cuffs - a proximal occluding cuff ...
... With its outstanding optical performance, the ... light used for all types of applications. ... micro-lens technology complies with the highest standards ... provides excellent shadow control within the surgical ...
... The DRE-200 ESU units use dedicated digital ... for processing data. This hardware allows parallel ... processing throughput, measuring tissue impedance 5000 times ... processed digitally, being converted to analog only ...
Medicine Products: